{"filing":{"accession_number":"0001171843-26-005294","cik":"0001799448","ticker":"ALGS","company_name":"Aligos Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"f8k_080526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184326005294/f8k_080526.htm"},"events":[{"id":25475,"run_id":23126,"accession_number":"0001171843-26-005294","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Q2 2026 financial results for Aligos Therapeutics, including condensed consolidated statements of operations and balance sheets, net loss per share of $(0.14), and R\u0026D/G\u0026A expense details. The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. Material to investors as it provides current financial position and operational performance metrics.","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26314,"accession_number":"0001171843-26-005294","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Aligos Therapeutics, including condensed consolidated statements of operations and balance sheets, net loss per share of $(0.14), and R\u0026D/G\u0026A expense details. The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. Material to investors as it provides current financial position and operational performance metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:54.481004+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26314,"accession_number":"0001171843-26-005294","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Aligos Therapeutics, including condensed consolidated statements of operations and balance sheets, net loss per share of $(0.14), and R\u0026D/G\u0026A expense details. The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the typical structure for quarterly earnings disclosures. Material to investors as it provides current financial position and operational performance metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:47:54.481004+00:00","company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","filing_date":"2026-08-06"}]}